Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, will publish its interim report for the second quarter 2026 on Thursday, August 6th, at 8.30 CEST. A webcast presentation and conference call will be held on the same day at 15.00 CEST. The presentation will be hosted by Jeff Borderching, CEO and President.
The presentation will be held in English and will be followed by a Q&A session.
Welcome to join via webcast or phone. Please dial in a few minutes before the presentation begins.
Webcast:
https://creo-live.creomediamanager.com/2d458eb8-6baa-4d79-880c-e7737e623e18
Number for dial-in participants:
Sweden: +46 (0)8 5051 0031
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13
The report, together with the presentation slides, will be available at www.immunovia.com.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit. www.immunovia.com.